BMY•benzinga•
Bristol Myers Squibb Receives European Commission Approval For Perioperative Regimen Of Neoadjuvant Opdivo (nivolumab) And Chemotherapy Followed by Adjuvant Opdivo For Resectable, High-Risk Non-Small Cell Lung Cancer With PD-L1 Expression ≥1%
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 16, 2025 by benzinga